<DOC>
	<DOC>NCT01968967</DOC>
	<brief_summary>This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.</brief_summary>
	<brief_title>Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Treated with a statin. Fasting LDLC &gt; 70 mg/dL and triglyceride &lt;=400 mg/dL. High or very high risk of incurring a cardiovascular event. Pregnant or breastfeeding females. Cardiovascular or cerebrovascular event of procedures during the past 30 days. Congestive heart failure NYHA class IV. Poorly controlled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>mixed dyslipidemia</keyword>
	<keyword>high risk of cardiovascular events</keyword>
	<keyword>multiple cardiovascular disease risk factors</keyword>
</DOC>